TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Arvinas, Inc.
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Arvinas will present preclinical data for ARV-393, a PROTAC BCL6 degrader targeting non-Hodgkin lymphoma, at the 2025 ASH Annual Meeting in Orlando, Florida.

Insights
ARVN   positive

Company is presenting novel preclinical research, advancing its protein degradation platform with potential therapeutic implications for lymphoma treatment